Autoimmune diseases such as multiple sclerosis arise when the immune system turns against the body itself. Yet for most of ...
A previously unknown mechanism that makes it possible for aggressive so-called triple-negative breast cancer to fine-tune its ...
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support ...
Pancreatic ductal adenocarcinoma (PDAC) is both the most common and the deadliest type of pancreatic cancer. Most treatment ...
Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...
Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these ...
DNA doesn’t just sit still inside our cells — it folds, loops, and rearranges in ways that shape how genes behave.
Pathogens can create sticky situations. When microbes invade the body to cause an infection, often one of their first lines ...
The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.
ELF3 axis enables luminal progenitor transformation in BRCA1-deficient breast cancer by reducing genomic instability and promoting progenitor identity.
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback